Trial Profile
Phase I Dose Escalation and Expansion Study of DS-7080a in Subjects With Neovascular Age-related Macular Degeneration or Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs DS 7080a (Primary) ; Ranibizumab
- Indications Age-related macular degeneration; Diabetic macular oedema
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 03 May 2018 Status changed from active, no longer recruiting to completed.
- 18 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 29 Jun 2017 Status changed from active, no longer recruiting to recruiting.